Each year, millions of individuals undergo cancer surgery that is intended to be curative or at least a necessary component of a curative regimen. Particularly for those patients whose cancer harbors cells that are resistant to chemotherapy or radiation, the extent of surgery often defines whether they will be a survivor or casualty of the disease. For many solid tumor types, the difference in survival between patients who undergo gross total resection and those who have residual bulky disease is often profound. With surgery being central to cancer survivorship, it is stunning how few resources have been invested in improving surgical outcomes, particularly in comparison to chemotherapeutic research and discovery. This article reviews recent advances related to developing targeted fluorescent agents to guide surgeons during cancer removal. The goal of these drugs and devices is to clearly distinguish cancer from normal tissue to improve surgical outcome for cancer patients.
THE UNMET CLINICAL NEED
In certain cases, distinguishing between cancer and normal tissue affects not only survival, but also quality of life for those who survive. For patients with cancer of the tongue, esophagus, or anus, preserving key normal tissues while completely resecting the cancer impacts the most basic functions of daily life.
In certain brain tumors, complete resection of nonmetastatic tumors has significant clinical value resulting in improved survival and reduced requirement for radiation or chemotherapy. In pediatric ependymoma patients in whom it is possible to achieve gross total resection (GTR) of posterior fossa lesions, patients experience an 80% event-free survival (EFS), and greater than 90% overall survival at 5 years even without subsequent radiation or chemotherapy. 1 By contrast, children with ependymomas and residual bulky disease after surgery require chemotherapy and radiation and experience a less than 50% 5-year EFS. 1 The situation is similar in young medulloblastoma patients, who with GTR followed by 18-Gy craniospinal radiation experience approximately 75% 5-year EFS. By contrast, patients with incompletely resected medulloblastomas and bulky residual disease require 36-Gy craniospinal radiation and experience only approximately 60% 5-year EFS. 2 The additional radiation and chemotherapy required in these cases frequently result in severe neurocognitive damage and other toxicities. 3, 4 The potential benefit of image-guided tumor resection for patients with glioblastoma multiforme, the most aggressive and common adult brain tumor, is more controversial. Skeptics correctly point out that diffuse invasion of glioma cells occurs well beyond any reasonable surgical margin and can even be found on the contralateral side of the brain at the time of diagnosis. However, it is also well known that surgical resection is the most effective therapy known to increase survival, and several studies have shown a clear improvement in survival with increased percentage of resection. 5, 6 Furthermore, fluorescent compounds that mark the tumor intraoperatively, such as 5-aminolevulinic acid (5-ALA), have been used to enhance the percentage of tumor resected, resulting in improved median survival, but increased deficits. 7 Likewise, multi-institutional trials of pediatric glioma patients show that long-term survival of pediatric high-grade glioma patients depends on GTR. 8 Presumably radiation therapy and chemotherapy are more effective for microscopic residual disease than for bulky disease because of the mechanisms of therapy resistance that flourish within the tumor microenvironment.
Limiting the frequency of second surgeries is a key goal of many investigators. Nearly 25% of women who undergo breast conservation surgery for breast cancer 9 and 20% of patients with prostate cancer 10 learn that the margins of their cancer were positive days to weeks after the surgery has been completed. Gaining insight into whether margins are free of detectable disease in real time during the initial surgery could reduce second surgeries for patients and ultimately result in significant cost savings to health care and insurance systems. Similarly, pathologists may be able to use benchtop imaging devices to identify the margins of a tumor that are most likely to be positive for cancer cells, thus focusing their time and effort on high-payoff regions rather than potentially missing key regions because there is simply too much tissue to evaluate microscopically. Furthermore, some cancer cells may appear identical or nearly identical to nonneoplastic cells by light microscopy, even with immunohistochemical stains. While it will need to be determined for each probe and each tumor type, it is conceivable that image-guided pathology will reveal microscopic disease that is undetectable by current methods.
INFORMING ADJUVANT THERAPY
In some instances, fluorescence imaging for cancer can guide more than surgery. In cases where cancer is thought to be localized to a single location based on computed tomography (CT) or magnetic resonance imaging (MRI) scans, fluorescence imaging can illuminate microscopic tumor studding that is below the limit of detection for other modalities. A recent study with fluoresceinlabeled folate revealed that surgeons observed an average of 7 tumor loci per ovarian cancer patient without the imaging agent and observed an average of 34 tumor loci per patient with fluorescence guidance. 11 Clearly, it would be futile to surgically remove dozens of microscopic cancer foci, and clearly, these patients require adjuvant therapy even if CT scans reveal a single site of disease and surgeons achieve a complete resection of that locus with clean surgical margins.
The National Cancer Institute created a devoted community of investigators who are advancing image-guided surgery strategies. The US Food and Drug Administration and its European counterpart have issued clear and helpful guidance documents to assist those who intend to create clinical candidates. [12] [13] [14] [15] [16] While reporting all progress in this rapidly evolving field is beyond the scope of a single review article, the following sections attempt to provide a high-level overview of progress and considerations related to ligands and devices for image-guided resection.
EMERGING IMAGE GUIDANCE MODALITIES
The use of imaging to guide tumor resection encompasses everything from simple white light illumination of a surgical field to the sophisticated neuronavigation systems that enable neurosurgeons to orient the surgical field to a preoperative MRI scan. Recent innovation in this field, driven by the need for better real-time intraoperative tools, has taken the form of optical, primarily fluorescence, imaging in real or near real time. Approaches across all surgical oncology indications include systems that measure differences in endogenous tissue properties and systems that depend on an exogenous imaging agent.
Systems that measure changes in endogenous tissue properties, including autofluorescence, exploit cellular characteristics that may be altered in neoplastic tissue. These include differences in DNA, amino acid, collagen, and glycolipid composition, porphyrin levels, hemoglobin content and saturation, oxidation, cellular architecture, or angiogenesis (for reviews, see Green et al, 17 Thill et al, 18 and Nakajima et al 19 ). These changes are inherently subtle, but consistent enough to offer additional information that supports lesion localization and margin assessment. Clinically, they have been applied, for example, in bedside margin assessment for breast cancer 18 and in indications such as head and neck cancer, 17 esophageal cancer, 20 and lung cancer. 19 More recently, mass spectrometry has been applied to analyze lipid profiles in aerosolized samples. 21, 22 
NONTARGETED IMAGING AGENTS
The use of an exogenous contrast agent may enhance differences between tumor and nontumor tissue and thereby simplify the distinction. Exogenous agents can be either nontargeted or targeted to antigens that are preferentially expressed in tumor, tumor vasculature, or microenvironment. Nontargeted agents provide contrast because of the general properties of tumors, rather than presence of a specific antigen, and they include unconjugated fluorescent dyes and a subset of nanoparticles. Unconjugated fluorescent dyes such as fluorescein, 23 methylene blue, 24 or indocyanine green (ICG) 23, 25 can be delivered locally or systemically and accumulate in areas of tumor tissue that have disrupted or altered tumor vasculature and drainage.
The metabolic agent 5-ALA induces production of fluorescent protoporphyrin IX in tumor cells; 5-ALA has been used in a variety of clinical settings, including photochemotherapy in the FIGURE 1. Detection of tumors in a mouse medulloblastoma model using BLZ-100 fluorescence. A, Odyssey image of whole brain. Fluorescence from the gross tumor is evident in the lower left quadrant. Signal in tumor was about 20-fold higher than in normal brain. A fluorescent spot that was well above background was noted (arrow). B, Hematoxylin-eosin-stained sections showed a small tumor lesion in this area of the brain. C, High-resolution image of the area delineated by the blue box in B. Scale bar = 138 μm. dermatology setting, detection of bladder tumors following interstitial delivery, and detection of glioma following systemic delivery. A randomized phase III clinical trial in adult glioma showed a significant increase in "complete" resections compared with conventional surgery (65% vs 36%), with complete resection significantly influencing progression-free survival. 26 A prospective comparison with intraoperative MRI has shown that the use of 5-ALA can improve detection of tumor, particularly in infiltrative zones. 27 Unfortunately, many low-grade and pediatric brain tumors do not produce clinically useful fluorescence following 5-ALA administration. 28, 29 Because of its excitation in the ultraviolet and emission in the visible spectrum, visualization of protoporphyrin IX fluorescence is restricted to within a few millimeters of the tissue surface. Normal brain tissue can obscure 5-ALAinduced fluorescence, in some cases resulting in residual tumor being left behind and repeat surgery. 30 
NANOPARTICLES
A variety of nanoparticle formats are being investigated for fluorescence-guided resection as well as diagnostic imaging. Nontargeted nanoparticles, such as unconjugated dyes, can enter and be retained within tumors because of EPR (enhanced permeability and retention), an effect of tumor vasculature that is nonspecific and varies with the size and type of lesion. Because they have large surface areas and can be functionalized, nanoparticles can be targeted to antigens as well as carry multiple "payloads," including fluorescent dyes, radioactive tags for imaging or therapeutic utility, and agents for photodynamic or photothermal therapy. The utility of near-infrared (NIR) fluorescent dyes is well recognized in the field, 31 and many nanoparticle-NIR dye conjugates are being developed. Although these conjugates can provide very intense labeling and good contrast, they face significant technical and regulatory hurdles for clinical applications. Nanoparticles intended solely for imaging will have a different risk-benefit profile as compared with those used for therapeutic purposes, 32 requiring them to be safer. Early clinical development has been initiated with C-dots, an integrin-targeting nanoparticle that is used for preoperative positron emission tomography imaging as well as intraoperative fluorescence imaging. 33 
TARGETED IMAGING AGENTS
Other targeted imaging agents have been constructed using dye conjugates with antibodies, peptides, or natural ligands to tumor targets. A number of RGD-containing peptides are being developed to target integrins on tumor vasculature. 34 These probes will highlight tumor vasculature and in some cases tumor cells themselves. Another approach that focuses on the tumor microenvironment uses tumor-associated enzymes (e.g., caspase) to cleave imaging prodrugs into fluorescing metabolites. 35, 36 There have been several preclinical studies and a few clinical trials of approved therapeutic antibodies conjugated to NIR fluorophores; these include cetuximab and panitumumab (epidermal growth Single arm Detection by imaging system NCT02280954 factor receptor), trastuzumab (HER-2), and bevacizumab (vascular endothelial growth factor). [37] [38] [39] Because of their large size, antibody conjugates may penetrate less effectively into tumor tissue compared with small molecule, aptamer, or peptide conjugates. Small-molecule conjugates are being developed that target folate receptor α and PSMA. 40 As noted above, a folate-fluorescein isothiocyanate (FITC) conjugate was evaluated for intraoperative imaging during ovarian cancer resection, where fluorescence imaging resulted in identification of peritoneal metastases that were not visible to surgeons using white light alone. 11 While offering high specificity for tumors expressing the targeted antigen, these conjugates are not likely to be broadly applicable across multiple tumor types. The cationic peptide chlorotoxin is internalized by cancer cells in a wide variety of solid tumor indications. 41, 42 A radiolabeled chlorotoxin peptide validated these findings in humans. [43] [44] [45] Furthermore, BLZ-100, a variant of chlorotoxin conjugated to a form of ICG, is able to distinguish very small foci of brain tumor cells from normal brain (Fig. 1) . Compared with nontargeted agents that rely on disrupted blood-brain barrier and EPR, molecules that specifically target cells and are internalized have the potential to distinguish cancer from normal tissue on a near cell-by-cell basis provided that high-resolution detection devices are used.
Exploiting more general properties of cancer cells is a strategy that may lead to other imaging agents that can be applied to multiple tumor types. Examples of such approaches include a phospholipid ether analog that targets lipid raft structures 46 and probes that are cleaved by extracellular matrix enzymes overexpressed at tumor borders, such as cathepsins and matrix metalloproteinase. 47 One example of this technology is a cell-penetrating peptide that is protected until the probe is cleaved or processed by the matrix metalloproteinase enzymes, after which the peptide penetrates nearby cells. 48 This approach ensures that the activated probe is retained in the tissue surrounding the site of activation, which is important for maintenance of distinct tumor boundary imaging throughout the time frame of a surgery.
TARGETING AGENT CONSIDERATIONS
The observation that some fluorescent molecules preferentially distribute to some cancers compared with adjacent tissue was first made over 50 years ago. These agents have not advanced to human clinical use primarily because the disrupted barriers in tumors are heterogeneous, so some regions of cancer are not detected. Also, some nonneoplastic tissues surrounding the tumor nonspecifically take up the agents as well. Hence, both sensitivity and specificity are problems, and these are the 2 parameters that are critical for providing useful information to surgeons. For this reason, many investigators and clinicians favor targeted agents, particularly those that bind directly to tumor cells with sufficient affinity or avidity that tumor cell, rather than interstitial or peritumoral fluid, is marked by fluorescent signal.
DEVICE CONSIDERATIONS
Most new fluorescent imaging agents are being developed with probes that emit in the NIR range because normal tissues have little autofluorescence at these wavelengths and because the light passes through small amounts of tissue that might lie between the camera and the fluorescent tissue (Fig. 2) . The devices for detecting NIR fluorescence are evolving rapidly and include endoscopes or exoscopes, surgical microscopes, and robotic systems, most incorporating CCD camera technology. 50, 51 Devices that collect and integrate images over short periods may have superior sensitivity compared with microscopes, but devices that can display high-definition images in real time will likely be preferred. For surgical margin evaluation, particularly in deep pockets during tumor debulking, flexible devices that can "see" around corners will provide an advantage over cameras or microscopes that are suspended over the patient.
ECONOMIC CONSIDERATIONS OF DEVELOPING MOLECULAR IMAGING AGENTS
The US Food and Drug Administration regulates imaging agents as drugs. Published guidance documents and regulatory precedent focus on safety and the predictive value of the agents for accurately distinguishing cancer from normal tissue. As such, the cost of nonclinical studies, manufacturing, and early-stage clinical and registration trials will often exceed US $100 million regardless of the market potential. Unlike chemotherapeutic agents that are prescribed for months or years, imaging agents are often used only once per patient so the potential to recover research and development costs is challenging.
Targeting molecules that bind to many types of cancer have potential to help more patients than those developed for a narrow subclass of cancer patients and may be more economically viable to develop. That said, there are certain instances in which a target is very highly expressed on a specific type of cancer cell and in which residual microscopic disease cannot be adequately addressed by adjuvant therapy because of inherent resistance to chemotherapy or radiation therapy. In these situations, agents with exceptional tumor-to-background ratio coupled with exquisitely sensitive devices could benefit patients and still be economically viable.
CONCLUSIONS
It seems to be only a matter of time before image-guided surgery is commonplace, and surgeons will reminisce about trying to distinguish cancer from normal tissue using their eyes, fingers, and thumbs. In the meantime, the race is on among device designers and manufacturers. Clinical proof-of-concept experiments with intriguing molecular imaging agents reveal the potential power of this approach, and increasingly candidate agents are being tested in larger numbers of cancer patients ( Table 1 ). The evolution of image guidance will likely be to surgeons and pathologists what the CT or MRI scan was to radiologists. Importantly, these imaging modalities provide new information to clinicians rather than absolute diagnostics. Thus, medical judgment, experience, and expertise will continue to play a key role to minimize both undertreatment and overtreatment of cancer patients following image-guided tumor resection.
